ESPR · Esperion Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.10M | - | $87.31M | $82.39M | $65.00M | - | $51.63M | $73.83M | $137.74M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $8.99M | - | $14.13M | $7.24M | $12.56M | - | $10.40M | $11.46M | $13.40M | - |
| SG&A | $43.12M | - | $41.85M | $39.51M | $43.00M | - | $39.98M | $44.19M | $41.99M | - |
| Total Operating Expenses | $86.69M | - | $97.27M | $75.29M | $87.09M | - | $67.66M | $71.25M | $65.47M | - |
| D&A | $27.0K | - | - | - | $26.0K | - | - | - | $0 | - |
| Operating Income | ($6.58M) | - | ($9.96M) | $7.09M | ($22.10M) | - | ($16.03M) | $2.58M | $72.27M | - |
| Interest Expense | $19.80M | - | $22.05M | $20.49M | $14.02M | - | $15.08M | $14.54M | $14.02M | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($25.20M) | - | ($31.33M) | ($12.72M) | ($40.45M) | - | ($29.52M) | ($61.92M) | $61.02M | - |
| EPS - Basic | ($0.10) | - | ($0.16) | ($0.06) | ($0.21) | - | ($0.15) | ($0.33) | $0.36 | - |
| EPS - Diluted | ($0.10) | - | ($0.16) | ($0.06) | ($0.21) | - | ($0.15) | ($0.33) | $0.34 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $156.16M | $167.85M | $92.45M | $86.06M | $114.63M | $144.76M | $144.72M | $189.30M | $226.61M | $82.25M |
| Accounts Receivable | $132.35M | $140.19M | $118.98M | $107.75M | $81.29M | $80.14M | $67.82M | $60.36M | $54.61M | $48.49M |
| Inventory | $104.21M | $105.12M | $108.54M | $114.47M | $99.32M | $94.49M | $80.10M | $84.47M | $73.09M | $65.62M |
| Accounts Payable | $68.41M | $65.07M | $77.51M | $74.70M | $71.99M | $51.65M | $34.86M | $47.67M | $28.43M | $31.72M |
| Current Assets | $459.46M | $462.57M | $360.46M | $342.60M | $318.78M | $338.00M | $307.56M | $345.11M | $365.61M | $201.06M |
| Total Assets | $462.53M | $465.89M | $364.02M | $347.08M | $324.03M | $343.82M | $314.11M | $352.32M | $373.06M | $205.80M |
| Current Liabilities | $300.36M | $300.81M | $359.03M | $298.80M | $270.97M | $246.23M | $165.87M | $175.34M | $164.51M | $156.22M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $770.46M | $767.85M | $815.38M | $780.59M | $750.24M | $732.54M | $684.32M | $696.54M | $667.36M | $660.79M |
| Stockholders' Equity | ($307.93M) | ($301.96M) | ($451.36M) | ($433.51M) | ($426.21M) | ($388.72M) | ($370.21M) | ($344.22M) | ($294.30M) | ($454.99M) |
| Retained Earnings | ($1.65B) | ($1.62B) | ($1.69B) | ($1.65B) | ($1.64B) | ($1.60B) | ($1.58B) | ($1.55B) | ($1.49B) | ($1.55B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($27.72M) | - | - | - | ($22.63M) | - | - | - | $53.83M | - |
| Investing Cash Flow | ($189.0K) | - | - | - | $0 | - | - | - | ($73.0K) | - |
| Financing Cash Flow | $16.22M | - | - | - | ($7.50M) | - | - | - | $90.61M | - |
| CapEx | $189.0K | - | - | - | $0 | - | - | - | $73.0K | - |
| Free Cash Flow | ($27.91M) | - | - | - | ($22.63M) | - | - | - | $53.76M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -8.2% | - | -11.4% | 8.6% | -34.0% | - | -31.0% | 3.5% | 52.5% | - |
| EBITDA margin | -8.2% | - | - | - | -34.0% | - | - | - | 52.5% | - |
| Net margin | -31.5% | - | -35.9% | -15.4% | -62.2% | - | -57.2% | -83.9% | 44.3% | - |
| Free cash flow margin | -34.8% | - | - | - | -34.8% | - | - | - | 39.0% | - |
| FCF / Net income | 1.11 | - | - | - | 0.56 | - | - | - | 0.88 | - |
| R&D / Revenue | 11.2% | - | 16.2% | 8.8% | 19.3% | - | 20.1% | 15.5% | 9.7% | - |
| SG&A / Revenue | 53.8% | - | 47.9% | 48.0% | 66.2% | - | 77.4% | 59.8% | 30.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.0% | - |
| Return on assets | -5.4% | - | -8.6% | -3.7% | -12.5% | - | -9.4% | -17.6% | 16.4% | - |
| Return on equity | 8.2% | - | 6.9% | 2.9% | 9.5% | - | 8.0% | 18.0% | -20.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.53 | 1.54 | 1.00 | 1.15 | 1.18 | 1.37 | 1.85 | 1.97 | 2.22 | 1.29 |
| Quick ratio | 1.18 | 1.19 | 0.70 | 0.76 | 0.81 | 0.99 | 1.37 | 1.49 | 1.78 | 0.87 |
| Cash ratio | 0.52 | 0.56 | 0.26 | 0.29 | 0.42 | 0.59 | 0.87 | 1.08 | 1.38 | 0.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.3x | - | -0.5x | 0.3x | -1.6x | - | -1.1x | 0.2x | 5.2x | - |
| Equity multiplier | -1.50 | -1.54 | -0.81 | -0.80 | -0.76 | -0.88 | -0.85 | -1.02 | -1.27 | -0.45 |
| Liabilities / Assets | 1.67 | 1.65 | 2.24 | 2.25 | 2.32 | 2.13 | 2.18 | 1.98 | 1.79 | 3.21 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.24 | 0.24 | 0.20 | - | 0.16 | 0.21 | 0.37 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 603d | - | 497d | 477d | 457d | - | 479d | 298d | 145d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 7.9x | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 8.6x | - | 6.1x | 2.3x | 4.3x | - | 6.2x | 5.7x | 3.7x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | 3.9x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 23.2% | - | 69.1% | 11.6% | -52.8% | - | 52.0% | 186.3% | 466.1% | - |
| Revenue CAGR (3y) | 48.8% | - | 66.3% | 63.5% | 51.1% | - | 53.0% | 22.0% | 158.5% | - |
| Revenue CAGR (5y) | 58.6% | - | 86.9% | -17.2% | 104.0% | - | 120.9% | 137.3% | -1.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 70.2% | - | 37.9% | 175.1% | - | - | 41.8% | - | - | - |
| Net income growth (YoY) | 37.7% | - | -6.1% | 79.5% | - | - | 28.4% | -24.0% | - | - |
| EPS growth (YoY) | 52.4% | - | -6.7% | 81.8% | - | - | 59.5% | 28.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | -35.6% | - |
| FCF growth (YoY) | -23.3% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | -10.1% | - |
| Book value growth (YoY) | 27.8% | 22.3% | -21.9% | -25.9% | -44.8% | 14.6% | 9.7% | 7.5% | 10.7% | -40.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$551.93M totalCollaboration Revenue$243.57M · 44.1%
Product$159.57M · 28.9%
Royalty Revenue From DSEAnd Sale Of Bulk Tablets And Milestones Received$148.80M · 27.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Esperion Therapeutics against the 5 most active filers in the same SIC group.